Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Endo to Pay $2.3 Million to Settle Antitrust Claims by 18 States

July 19, 2019, 7:34 PMUpdated: July 19, 2019, 10:21 PM

Endo International Plc agreed to pay $2.3 million to settle allegations by 18 states that the drugmaker paid a competitor to keep a generic version of its lucrative Lidoderm pain patch off the market.

Utah and the other states said in a complaint filed July 19 in San Francisco federal court that Endo bought off Watson Laboratories Inc. in 2012 to delay by more than a year the launch of a generic lidocaine patch. The settlement agreement was filed separately from the complaint.

“Endo knew that generic competition would decimate its Lidoderm sales and that any delay in generic competition ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.